Non-target screening using chromatography coupled to high-resolution mass spectrometry is a powerful tool in environmental ...
-- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 ...
BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...
– Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 ...
A recent organizational review of the Regional District of Central Kootenay has confirmed that the RDCK’s core challenges are ...
The healthcare investor conference MedCity INVEST, scheduled for May 20-21 at the Willis Tower in Chicago, will spotlight strategic priorities for health systems at a time when many face uncertainty ...
I’ve learned that limited resources are a clarifier, not a constraint. When two priorities matter equally, I choose the sequence that strengthens our foundation first—because that early focus creates ...
One leader at Blue Shield California shares the company's strategic priorities. Dr. Pushwaz Virk serves as the Medical Director of Clinical Product Development, Care Innovation, and Technology ...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results